Comparative Pharmacology
Head-to-head clinical analysis: CONSTULOSE versus GO EVAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSTULOSE versus GO EVAC.
CONSTULOSE vs GO-EVAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lactulose is a synthetic disaccharide that is not absorbed in the small intestine. In the colon, it is metabolized by bacteria to short-chain fatty acids, leading to an osmotic effect that draws water into the bowel, thereby softening stools and increasing bowel motility. In hepatic encephalopathy, lactulose acidifies the colonic environment, promoting the conversion of ammonia (NH3) to ammonium (NH4+), which is trapped and excreted in feces.
Promotes gastrointestinal motility by acting as a stimulant laxative, likely through direct irritation of the colonic mucosa and possibly via local effects on enteric neurons.
10-20 g (15-30 mL) orally once daily, increased to 30-45 g (45-60 mL) if needed; or 30-45 g (45-60 mL) orally every 6-8 hours for hepatic encephalopathy.
10 mg orally once daily, with or without food.
None Documented
None Documented
Not applicable due to minimal systemic absorption; local action in colon. In cases of systemic absorption, half-life is not clinically relevant.
4.5-6 hours in healthy volunteers; prolonged to 10-14 hours in elderly patients and those with moderate renal impairment (CrCl 30-50 mL/min).
Primarily fecal (unchanged); minimal systemic absorption (<3%), thus negligible renal excretion.
Primarily renal; approximately 60% eliminated unchanged in urine within 24 hours, with 20% as metabolites. Biliary/fecal excretion accounts for 15-20%, and the remainder is metabolized via glucuronidation.
Category C
Category C
Osmotic Laxative
Osmotic Laxative